Literature DB >> 10845897

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants.

S Kulkarni1, R Powles, J Treleaven, U Riley, S Singhal, C Horton, B Sirohi, N Bhagwati, S Meller, R Saso, J Mehta.   

Abstract

Incidences of and risk factors for Streptococcus pneumoniae sepsis (SPS) after hematopoietic stem cell transplantation were analyzed in 1329 patients treated at a single center between 1973 and 1997. SPS developed in 31 patients a median of 10 months after transplantation (range, 3 to 187 months). The infection was fatal in 7 patients. The probability of SPS developing at 5 and 10 years was 4% and 6%, respectively. Age, sex, diagnosis, and graft versus host disease (GVHD) prophylaxis did not influence the development of SPS. Allogeneic transplantation (10-year probability, 7% vs 3% for nonallogeneic transplants; P =.03) and chronic GVHD (10-year probability, 14% vs 4%; P =.002) were associated with significantly higher risk for SPS. All the episodes of SPS were seen in patients who had undergone allograft or total body irradiation (TBI) (31 of 1202 vs 0 of 127; P =.07). Eight patients were taking regular penicillin prophylaxis at the time of SPS, whereas 23 were not taking any prophylaxis. None of the 7 patients with fatal infections was taking prophylaxis for Pneumococcus. Pneumococcal bacteremia was associated with higher incidences of mortality (6 of 15 vs 1 of 16; P =.04). We conclude that there is a significant long-term risk for pneumococcal infection in patients who have undergone allograft transplantation, especially those with chronic GVHD. Patients who have undergone autograft transplantation after TBI-containing regimens also appear to be at increased risk. These patients should receive lifelong pneumococcus prophylaxis. Consistent with increasing resistance to penicillin, penicillin prophylaxis does not universally prevent SPS, though it may protect against fatal infections. Further studies are required to determine the optimum prophylactic strategy in patients at risk. (Blood. 2000;95:3683-3686)

Entities:  

Mesh:

Year:  2000        PMID: 10845897

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.

Authors:  Dipenkumar Modi; Hyejeong Jang; Seongho Kim; Abhinav Deol; Lois Ayash; Divaya Bhutani; Lawrence G Lum; Voravit Ratanatharathorn; Richard Manasa; Kendra Mellert; Joseph P Uberti
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

Review 2.  How I treat sickle cell disease with hematopoietic cell transplantation.

Authors:  Elizabeth O Stenger; Shalini Shenoy; Lakshmanan Krishnamurti
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

Review 3.  Pathogenesis and management of graft-versus-host disease.

Authors:  Sung W Choi; John E Levine; James L M Ferrara
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

4.  B cell-specific deficiencies in mTOR limit humoral immune responses.

Authors:  Shuling Zhang; Margaret Pruitt; Dena Tran; Wendy Du Bois; Ke Zhang; Rushi Patel; Shelley Hoover; R Mark Simpson; John Simmons; Joy Gary; Clifford M Snapper; Rafael Casellas; Beverly A Mock
Journal:  J Immunol       Date:  2013-07-15       Impact factor: 5.422

Review 5.  Pneumococcal arthritis affects performance status in patients with chronic GVHD of the skin following allogeneic bone marrow transplantation.

Authors:  N Sakata; M Yasui; K Kawa
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

6.  Functional hyposplenism after hematopoietic stem cell transplantation.

Authors:  J Rozmus; K Mallhi; J Ke; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 8.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

9.  Chronic GvHD decreases antiviral immune responses in allogeneic BMT.

Authors:  Mohammad S Hossain; John D Roback; Brian P Pollack; David L Jaye; Amelia Langston; Edmund K Waller
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

10.  Bacterial meningitis in hematopoietic stem cell transplant recipients: a population-based prospective study.

Authors:  K E B van Veen; M C Brouwer; A van der Ende; D van de Beek
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.